BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 32212809)

  • 1. Evaluation of p53 and Its Target Gene Expression as Potential Biomarkers of Cholangiocarcinoma in Thai Patients.
    Puetkasichonpasutha J; Namwat N; Sa-Ngiamwibool P; Titapun A; Suthiphongchai T
    Asian Pac J Cancer Prev; 2020 Mar; 21(3):791-798. PubMed ID: 32212809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MCM2 promotes the proliferation, migration and invasion of cholangiocarcinoma cells by reducing the p53 signaling pathway.
    Wang CL; Liu XY; Wang YH; Zhang Z; Wang ZD; Zhou GQ
    Yi Chuan; 2022 Mar; 44(3):230-244. PubMed ID: 35307646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The microRNA-15a-PAI-2 axis in cholangiocarcinoma-associated fibroblasts promotes migration of cancer cells.
    Utaijaratrasmi P; Vaeteewoottacharn K; Tsunematsu T; Jamjantra P; Wongkham S; Pairojkul C; Khuntikeo N; Ishimaru N; Sirivatanauksorn Y; Pongpaibul A; Thuwajit P; Thuwajit C; Kudo Y
    Mol Cancer; 2018 Jan; 17(1):10. PubMed ID: 29347950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant methylation of HTATIP2 and UCHL1 as a predictive biomarker for cholangiocarcinoma.
    Nanok C; Jearanaikoon P; Proungvitaya S; Limpaiboon T
    Mol Med Rep; 2018 Mar; 17(3):4145-4153. PubMed ID: 29359783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulated expression of HSP70 in correlation with clinicopathology of cholangiocarcinoma.
    Boonjaraspinyo S; Boonmars T; Kaewkes S; Laummaunwai P; Pinlaor S; Loilome W; Yongvanit P; Wu Z; Puapairoj A; Bhudhisawasdi V
    Pathol Oncol Res; 2012 Apr; 18(2):227-37. PubMed ID: 21750953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma?
    Sasaki M; Sato Y; Nakanuma Y
    Histopathology; 2022 Apr; 80(5):859-868. PubMed ID: 35076959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profiling of downregulated blood-circulating miR-150-5p as a novel tumor marker for cholangiocarcinoma.
    Wu X; Xia M; Chen D; Wu F; Lv Z; Zhan Q; Jiao Y; Wang W; Chen G; An F
    Tumour Biol; 2016 Nov; 37(11):15019-15029. PubMed ID: 27658773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HSDL2 knockdown promotes the progression of cholangiocarcinoma by inhibiting ferroptosis through the P53/SLC7A11 axis.
    Ma S; Ma Y; Qi F; Lei J; Chen F; Sun W; Wang D; Zhou S; Liu Z; Lu Z; Zhang D
    World J Surg Oncol; 2023 Sep; 21(1):293. PubMed ID: 37718459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Annexin A1: A new immunohistological marker of cholangiocarcinoma.
    Hongsrichan N; Rucksaken R; Chamgramol Y; Pinlaor P; Techasen A; Yongvanit P; Khuntikeo N; Pairojkul C; Pinlaor S
    World J Gastroenterol; 2013 Apr; 19(16):2456-65. PubMed ID: 23674846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of NRF2 polymorphism with cholangiocarcinoma prognosis in Thai patients.
    Khunluck T; Kukongviriyapan V; Puapairoj A; Khuntikeo N; Senggunprai L; Zeekpudsa P; Prawan A
    Asian Pac J Cancer Prev; 2014; 15(1):299-304. PubMed ID: 24528044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker.
    Utispan K; Thuwajit P; Abiko Y; Charngkaew K; Paupairoj A; Chau-in S; Thuwajit C
    Mol Cancer; 2010 Jan; 9():13. PubMed ID: 20096135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between promoter methylation of p14(ARF), TMS1/ASC, and DAPK, and p53 mutation with prognosis in cholangiocarcinoma.
    Xiaofang L; Kun T; Shaoping Y; Zaiqiu W; Hailong S
    World J Surg Oncol; 2012 Jan; 10():5. PubMed ID: 22230750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. lnc-PKD2-2-3, identified by long non-coding RNA expression profiling, is associated with pejorative tumor features and poor prognosis, enhances cancer stemness and may serve as cancer stem-cell marker in cholangiocarcinoma.
    Qiu G; Ma D; Li F; Sun D; Zeng Z
    Int J Oncol; 2019 Jul; 55(1):45-58. PubMed ID: 31059014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary Sclerosing Cholangitis-Associated Cholangiocarcinoma Demonstrates High Intertumor and Intratumor Heterogeneity.
    Kamp EJCA; Peppelenbosch MP; Doukas M; Verheij J; Ponsioen CY; van Marion R; Bruno MJ; Groot Koerkamp B; Dinjens WNM; de Vries AC
    Clin Transl Gastroenterol; 2021 Oct; 12(10):e00410. PubMed ID: 34608877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trefoil factors: tumor progression markers and mitogens via EGFR/MAPK activation in cholangiocarcinoma.
    Kosriwong K; Menheniott TR; Giraud AS; Jearanaikoon P; Sripa B; Limpaiboon T
    World J Gastroenterol; 2011 Mar; 17(12):1631-41. PubMed ID: 21472131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of combined hepatocellular-cholangiocarcinoma through transdifferentiation and dedifferentiation in p53-knockout mice.
    Liu Y; Xin B; Yamamoto M; Goto M; Ooshio T; Kamikokura Y; Tanaka H; Meng L; Okada Y; Mizukami Y; Nishikawa Y
    Cancer Sci; 2021 Aug; 112(8):3111-3124. PubMed ID: 34051011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of potential targets to enhance the sensitivity of cholangiocarcinoma cells to anticancer drugs.
    Sanchon-Sanchez P; Briz O; Macias RIR; Abad M; Sanchez-Martin A; Marin JJG; Lozano E
    Biomed Pharmacother; 2023 Dec; 168():115658. PubMed ID: 37832404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged oxidative stress down-regulates Early B cell factor 1 with inhibition of its tumor suppressive function against cholangiocarcinoma genesis.
    Armartmuntree N; Murata M; Techasen A; Yongvanit P; Loilome W; Namwat N; Pairojkul C; Sakonsinsiri C; Pinlaor S; Thanan R
    Redox Biol; 2018 Apr; 14():637-644. PubMed ID: 29169115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysregulated microRNA expression profiles in cholangiocarcinoma cell-derived exosomes.
    Kitdumrongthum S; Metheetrairut C; Charoensawan V; Ounjai P; Janpipatkul K; Panvongsa W; Weerachayaphorn J; Piyachaturawat P; Chairoungdua A
    Life Sci; 2018 Oct; 210():65-75. PubMed ID: 30165035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the ∆133p53 isoform can restore chemosensitivity in 5-fluorouracil-resistant cholangiocarcinoma cells.
    Nutthasirikul N; Hahnvajanawong C; Techasen A; Limpaiboon T; Leelayuwat C; Chau-In S; Jearanaikoon P
    Int J Oncol; 2015 Dec; 47(6):2153-64. PubMed ID: 26459801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.